Gain Therapeutics, Inc. (GANX) investor relations documents from the company's IR site: 2 presentations, 2 press releases; latest deck 2026-05-14. Read in-app with summaries. First-party data.
View: Gain Therapeutics (NASDAQ: GANX) is a biotech firm developing GT-02287, a disease-modifying Parkinson’s therapy, with Phase 2 trials scheduled for Q3 2026.
| Published | Type | Document |
|---|---|---|
| 2026-08-11 | Press release | Press release |
| 2026-05-14 | Presentation | View |
| 2026-01-06 | Presentation | View |
| 2024-11-14 | Press release | Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update |
GANX overview · GANX earnings · GANX financials · GANX KPIs · GANX ownership · GANX peers · GANX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.